Lichen Sclerosus of External Female Genital Organs
Conditions
Keywords
acetonide, triamcinolone, Vulvar Diseases, Administration, Cutaneous, Syringes, Tattooing
Brief summary
This research is about a genital disease known as Lichem Sclerosus and Atrophic. It mainly affects women over 18 years of age. The treatment will involve injections of a medicine that contains cortisone, using two different methods: with a syringe and a needle or with a tattoo machine. Before and after treatment, they will see if women feel pain, itching, burning, scratching or difficulty having sexual intercourse.
Detailed description
There is evidence that injectable triamcinolone has an effect on reducing the symptoms of lichen sclerosus and atrophic. After randomizing the vulva, the vulva will be anesthetized with lidocaine infiltrations. After 15 minutes, interventions will begin. Triamcinolone will be injected using two different techniques: syringes & needles in one side and with tattoo machine (MMP technique) in other side. The outcomes will be evaluated according to the criteria of pain, itching, burning, itching and difficulty in sexual penetration
Interventions
PROCEDUREInfiltration of triamcinolone acetonide (2mg/ml) through syringes and needles
Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles
PROCEDUREInfiltration of triamcinolone acetonide (40 mg/ml) with needles
Infiltration of triamcinolone acetonide (40 mg/ml) through needles of tattoo machine
Sponsors
Clinica Dermatologica Arbache ltda
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Prospective, randomized pilot study involving 20 participants with genital LEA, refractory to the use of high-potency topical corticosteroid therapy. In this investigation. The vulvas will be randomized as right side and left side
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Clinical and/or histopathological diagnosis of genital (vulvar, perineal or perianal) Lichen Sclerosus and Atrophicus (LEA), 2. Failure to regress symptoms after topical treatment with potent topical corticosteroid for at least 3 months, 3. Progressive deformity of the vulva, clitoris, perineal or perianal region during treatment with potent topical corticosteroids,
Exclusion criteria
* Absence of other skin diseases such as lichen planus, psoriasis, Crohn's disease and ulcerative colitis, * Commitment to use at least one form of adequate contraception (hormonal or barrier method) if sexually active or of childbearing potential (premenopausal or postmenopausal women for less than 2 years), * Willingness to fulfill the study requirements. Willing and able to follow the schedule of treatments and follow-up visits, * patient demonstrates mental and psychiatric health, * Signs of good hygiene and evidence that you can apply dressings until the injuries heal, * Diagnosis of pre-malignant or malignant genital (e.g. vulvar dysplasia, intraepithelial neoplasia or carcinoma), * Crural lymphadenopathy, * Absence of urinary incontinence, absence of immunological changes, absence of visceral neoplasia, absence of coagulation disorders (or use of anticoagulants), absence of immunosuppressive treatment (including) systemic corticosteroid therapy. * Patients/participants with previously known allergies or those detected during the interventions (anesthetics, topical antibiotics or other medications used in the trials), * If pregnancy occurs during the trial, the participant will be excluded from the investigation and referred to an obstetrician. If the patient wishes, her genitalia will be clinically monitored during pregnancy and breastfeeding, * Participants who are not collaborative or who are absent from regular visits. * Refusal to treat local infectious diseases that trigger intervention (parasitic, protozoal, bacterial, viral or fungal). * Participant with recurrent genital herpes simplex who refuses to undergo systemic antiviral therapy. * Identification during interventions of allergies to the medications used in the trial (anesthetics, topical antibiotics or other medications used in the trials), * Any disease or condition not explicitly related to the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Scoring System for Vulvar Lichen Sclerosus | one year | On each side of the randomized vulva, symptoms of itching, burning, pain and dyspareunia will be assessed before and after the intervention. The assessment will be carried out by the patient herself, on a scale of zero to 10, with zero being asymptomatic and 10 when the symptom is unbearable. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| evaluate the safety of both interventions | one year | ulcers, telangiectasias and local atrophies. Local or systemic infections. |
Countries
Brazil
Outcome results
None listed